Ozempic vaginal side effects: yeast, BV and dryness

Author: Jessica Lloyd
Senior Vulvovaginal Specialist Naturopath | BHSc(N) | ISSVD, ISSWSH, BSSM, ATMS

Last reviewed: July 20, 2026

Semaglutide is a medication used by people with diabetes to help manage blood sugar and insulin, and increasingly for weight loss. It is given by injection (Ozempic, Wegovy) or as a tablet (Rybelsus).

Ozempic, Wegovy and Rybelsus are all brand names for the same active ingredient: semaglutide. Ozempic and Rybelsus are approved for type 2 diabetes, while Wegovy is approved for weight management. Using Ozempic or Rybelsus for weight loss is an off-label use¹.

In the USA especially, semaglutide is now widely available through telehealth platforms and online weight-loss services, usually with a prescription attached. It has been enthusiastically promoted on social media, including to young women with PCOS, which is where a lot of the buzz – and the unsupervised use – comes from².

What this means for your vagina

Here is the short version, because you came to a vagina website for a reason. The manufacturers do not list vaginal or vulval problems as side effects of semaglutide. But a growing number of users are reporting them anyway, and the biology gives us a few plausible reasons why.

The most common vulvovaginal reports we see cluster around three things: recurrent yeast infections (thrush), bacterial vaginosis (BV), and urinary tract infections (UTIs) or UTI-like symptoms such as urgency and frequency.

People also mention vulval burning and sensitivity, vaginal dryness, changes in libido, and menstrual irregularities like late or erratic periods. A smaller number report unexpected vaginal bleeding.

Why might a blood-sugar drug reach all the way down there? Three threads run through this article: semaglutide changes your gut microbiome, it changes how your kidneys handle glucose and electrolytes (which changes your urine), and it works on GLP-1, a hormone that some vaginal and urinary bugs are very interested in. None of this is proven to cause vaginal symptoms yet – there is no direct research on semaglutide and the vagina – but it is where the clues point.

Gut, hormonal, vaginal and urinary tract side-effects of semaglutide

Common listed side effects of Wegovy, Ozempic and Rybelsus include nausea, vomiting, diarrhoea, abdominal pain and constipation³.

However, there is a growing body of anecdotal reports from some users of semaglutide – not listed by the manufacturer – describing hormonal disruption and urogenital symptoms.

Some users report menstrual irregularities such as erratic or delayed periods, while others describe an increase in recurrent yeast infections and disrupted vaginal flora.

A number are reporting a surge in infections like BV, yeast and UTIs that they hadn’t had in years, which only started after they began semaglutide.

These users report increased recurrent yeast infections, bacterial vaginosis (BV), urinary tract infections (UTIs), or urinary tract symptoms that suggest infection, such as increased frequency or urgency.

Other user-reported effects on the vulva and vagina include burning, sensitivity, dryness and changes to libido. It’s not yet clear why these effects happen while using the drug.

Vaginal yeast infections are more common in diabetics and those with blood sugar dysregulation, and some diabetes medications raise the risk further – SGLT2 inhibitors, a different class of drug that flushes glucose out through the urine, are a well-documented example⁴. But that doesn’t account for the reported urogenital and hormonal effects in semaglutide users, many of whom are not diabetic and do not have insulin resistance.

Vaginal bleeding from GLP-1 RAs

There is one published case report of a 44-year-old perimenopausal woman with type 2 diabetes who experienced what appeared to be dulaglutide-related vaginal bleeding⁵. Dulaglutide (Trulicity) is a cousin of semaglutide in the same GLP-1 receptor agonist family.

Beyond that single case, vaginal bleeding appears only rarely in patient-reported adverse-event databases for these drugs, and vaginal infections were not reported to the US Food and Drug Administration (FDA) as side effects in the semaglutide clinical trials¹⁸. In other words: this is uncommon and largely anecdotal, but not impossible. Any new or unexplained vaginal bleeding always deserves a proper medical assessment, semaglutide or not.

Semaglutide and the gut microbiome

The majority of side effects occur in the digestive system – nausea, vomiting, decreased appetite and abdominal cramping^3,11 – which points to the gut as a major site of action. We know semaglutide changes the gut microbiome, but it isn’t fully understood why the digestive side effects are so common.

We’ll get into exactly how it works a little further down.

While you might expect that unpleasant digestive symptoms would be bad for the gut, there is evidence that in obesity and type 2 diabetes, semaglutide can shift the gut microbiome in a helpful direction, offsetting some of the microbial damage caused by a high-fat diet^7,8.

Research shows the gut microbiome is involved in obesity and metabolic disorders, and that it changes with treatment⁹.

Rather than simply wiping out bacteria, semaglutide seems to reshape which bugs dominate – for example shifting the balance of Firmicutes and Bacteroidetes – and this reshaping is generally considered favourable in obesity and insulin resistance^7,8.

Insulin dysregulation and hormones

Insulin acts directly on the ovaries, sending a signal to produce testosterone. In insulin resistance, the extra insulin can set off a cascade of hormonal signals that interrupt normal menstrual cycles.

The most common insulin-resistance-related condition is polycystic ovarian syndrome (PCOS), now understood to be driven largely by excess insulin from resistance. It is less a purely hormonal condition than a blood sugar problem, but its most common features are skipped periods, hard-to-shift weight, and signs of excess androgens like facial hair and acne.

In a pharmacokinetic study, oral semaglutide did not meaningfully change the levels of the hormones in a combined oral contraceptive pill¹⁰.

Serious side effects of semaglutide

Serious listed side effects of semaglutide can include thyroid tumours and multiple endocrine neoplasia syndrome type 2, along with pancreatitis, vision changes, low blood sugar, kidney problems, allergic reactions and gallbladder problems^3,11.

These serious effects may give us some clues as to how the urinary tract and vagina got caught up in blood sugar management.

What to do if you’re experiencing urogenital side effects from Wegovy or Ozempic

Talk to your doctor and report your experience on Wegovy or Ozempic, so they can check the effect is coming from the drug and not another cause
Discuss whether skipping some injections helps the symptoms settle (it may take longer than a week to shift, so be mindful with any experiments and keep your doctor in the loop)
Explore other options with your doctor
Keep a symptom diary – it helps later when you’re trying to work out whether things have improved, worsened or stayed the same on Wegovy or Ozempic
If semaglutide isn’t a good fit, explore non-drug options with a functional medicine doctor, herbalist, nutritionist or naturopath who works with metabolic conditions

I want to stay on semaglutide – what can I do for non-severe symptoms?

For UTI and urinary tract symptoms, our Oral UTI Formula (herbal blend) is designed for this
For vaginal symptoms like BV, BV Rescue is our targeted option
A women’s-strength oral and vaginal probiotic, used as per Killing BV
Download and read Killing BV for treatment tips and tricks
Tools for clearing up a smelly vagina
Talk to an experienced healthcare practitioner about other ways to manage blood sugar and weight alongside Wegovy and Ozempic

How does semaglutide work?

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that mimics the hormone GLP-1. GLP-1 is made by the gut wall when we eat, stimulating the pancreas to release insulin and so lowering blood glucose.

When you eat, you release insulin to collect the glucose absorbed from food and clear it from the blood, where too much of it is dangerous. You also pass a little glucose in your urine, temporarily raising urinary glucose.

If you have diabetes or insulin resistance, far more insulin has to be released to capture all the glucose, which takes longer and creates a state of high blood sugar (hyperglycaemia). That rise in blood sugar also pushes more glucose into the urine, usually for longer than in people without insulin resistance.

This is why diabetics are prescribed insulin injections and medications like semaglutide and metformin: to boost insulin when it’s needed and keep blood sugar in a safe range.

How semaglutide affects the urogenital tract is not understood, and there is no direct research on it. There is, however, research on how semaglutide affects the kidneys and certain bacteria, which may offer some clues.

UNDERSTANDING INSULIN RESISTANCE
If you're a little unclear on how insulin and blood sugar do their important work, our resident insulin resistance expert, Josephine Cabrall, gives a great explanation in our insulin resistance article (https://myvagina.com/what-is-insulin-resistance/) - with excellent custom-made cartoons.

E. faecalis breaks down GLP-1 (UTIs, AV)

One study¹² showed that GLP-1 is used up by many strains of Enterococcus faecalis, a very common urinary tract pathogen and one of the major players in many cases of aerobic vaginitis (AV).

E. faecalis is a gut commensal, meaning it belongs in the digestive system – but it does not belong in any meaningful numbers in the urinary tract or vagina.

A protease secreted by E. faecalis, GelE – an established virulence factor – was responsible for inactivating GLP-1 by cleaving it. Cleaving, in bacteria-speak, means splitting or breaking the bonds within something else, in this case GLP-1.

These strains can disrupt the gut lining and, in effect, steal GLP-1 from the digestive system, where it’s needed for blood sugar management.

But this leaves us with more questions than answers. Can E. faecalis do the same in the vagina and urinary tract? Is there even GLP-1 in the epithelial cells of the vagina or urinary tract? And if we boost GLP-1 activity with semaglutide, would that in turn affect E. faecalis numbers?

E. coli increases after GLP-1 RAs (UTIs, AV)

In mice, giving a GLP-1 RA increased a component of Escherichia coli (caseinolytic protease B) and norepinephrine in the gut¹³, pointing to a rise in E. coli populations. E. coli is the number-one cause of UTIs and a frequent troublemaker in aerobic vaginitis.

Norepinephrine (noradrenaline) passed into the gut, with indirect evidence that the GLP-1 RA switched on the sympathetic nervous system in the intestinal tract¹³.

Under normal conditions the extra E. coli didn’t harm the mice, but in mice with colitis, bacteria were able to slip through the intestinal wall because the normally tight junctions had loosened¹³.

Impacts of GLP-1 RA drugs – what we know

The effects on the kidneys of prolonged GLP-1 RA treatment are largely unknown¹⁴
Increases urinary excretion of sodium, chloride and potassium¹⁴
Increases urinary pH¹⁴
Reduces excretion of magnesium, calcium and phosphate¹⁴
Suggestions of decreased NHE3 activity¹⁴
Increased post-eating (postprandial) blood pressure¹⁴

Those last few are worth noticing for a vagina article: a higher urinary pH changes the chemistry of the urine passing over the vulva, and shifting electrolytes changes the urine too. Whether that’s enough to nudge the vulvovaginal environment isn’t known, but it’s a reasonable thread to pull.

GLP-1 RA drugs for diabetics

There are several GLP-1 RA drugs, differing in their molecular structure and how long they keep working. Those differences translate into how effective the drug is, how well it’s tolerated, and its potential for side effects.

For example: how big is the molecule, and how long does it last in the body before it’s cleared (its half-life)? How closely does it resemble human GLP-1? All of this shapes how well the drug manages blood sugar and weight, and which side effects show up.

Native GLP-1 is very short-acting, with a short half-life¹⁵, which is exactly why the drug versions are engineered to hang around much longer.

Individual response to semaglutide can’t be predicted – some people love it, some it simply doesn’t agree with. The drugs worked well in clinical trials to lower blood glucose and achieve weight loss.

Kidney input

To understand how semaglutide might contribute to changes in microflora, we have to understand how the body manages glucose, and how other players – like microbes – make use of substances we produce, such as GLP-1.

Insulin release is one way your body deals with incoming glucose, but your kidneys do a lot of heavy lifting too.

Without getting into too much detail, the kidneys take up some of the glucose (renal glucose uptake), then, after a while, release it again (reabsorption) once the body has had time to deal with the rest of the glucose using insulin and other mechanisms^16,17.

Your kidneys hold on to glucose, but if they fill up you’ll pass some in your urine. The kidneys of diabetics don’t handle glucose in the same way as those of non-diabetics.

Use of semaglutide for weight loss alone (without type 2 diabetes)

In the USA in particular, many people use semaglutide as a weight-loss tool. Weight loss isn’t a use every semaglutide product is approved for, but it is a natural effect of managing blood glucose well. Semaglutide also reduces appetite, another job of our own GLP-1 hormone.

Using a drug for an effect it isn’t primarily approved for is called off-label use. Many drugs are used safely this way under medical supervision.

It’s currently unclear what proportion of users reporting urogenital and hormonal side effects have been diagnosed with insulin resistance or type 2 diabetes, and how many are using semaglutide for weight loss alone.

Frequently asked questions

Can Ozempic or Wegovy cause yeast infections and BV?

The manufacturers don’t list yeast infections or BV as side effects, and there’s no direct study proving semaglutide causes them. But plenty of users report a run of thrush, BV or UTIs starting after they began the drug. The likely threads are changes to the gut microbiome, changes to the urine as the kidneys handle glucose and electrolytes differently, and effects on GLP-1 that some vaginal and urinary bugs feed on. If you’re getting recurrent infections, it’s worth telling your prescriber and treating the infections properly rather than just riding them out.

Is semaglutide safe in pregnancy or when trying to conceive?

Semaglutide is not recommended in pregnancy, and there’s a published case of a woman developing severe pregnancy sickness (hyperemesis gravidarum) linked to semaglutide⁶. Manufacturers advise stopping it well before a planned pregnancy. There’s a twist worth knowing: because these drugs can improve insulin resistance and help weight come down, some people with PCOS find their fertility returns unexpectedly, so contraception matters if you don’t want to conceive. Talk to your prescriber about timing if pregnancy is on the cards.

Will Ozempic mess with my periods or hormones?

Some users report late, erratic or changed periods. Part of that is likely the weight change and improved insulin sensitivity, which genuinely shifts hormones – especially in PCOS, where excess insulin drives a lot of the trouble. In the lab, oral semaglutide didn’t meaningfully change the hormone levels of a combined contraceptive pill¹⁰, so it isn’t thought to make the pill stop working. If your cycle changes a lot, it’s worth mentioning to your doctor.

This article is general information and not a substitute for personalised medical advice. If you are worried about your symptoms – including recurrent infections, unexplained bleeding or changes to your cycle while taking semaglutide – please see an experienced practitioner.

References

Ghusn W, De la Rosa A, Sacoto D, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Network Open. 2022;5(9):e2231982. https://pmc.ncbi.nlm.nih.gov/articles/PMC9486455/
Keating SK, Wild CEK. Semaglutide and social media: implications for young women with polycystic ovarian syndrome. The Lancet Child & Adolescent Health. 2023;7(5):301–303. https://pubmed.ncbi.nlm.nih.gov/36803633/
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Yokoyama H, Nagao A, Watanabe S, Honjo J. Incidence and risk of vaginal candidiasis associated with sodium–glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes. Journal of Diabetes Investigation. 2019;10(2):439–445. https://pmc.ncbi.nlm.nih.gov/articles/PMC6400166/
Vaccaro CJ, Zaidi SMH, Iskander PA, McFadden E. A case of dulaglutide-induced vaginal bleed. Cureus. 2023;15(5):e38774. https://pmc.ncbi.nlm.nih.gov/articles/PMC10249759/
Okeke IG, Camarda AR, Okeke R, Chaughtai S. Semaglutide-induced hyperemesis gravidarum. JCEM Case Reports. 2024;2(2):luad167. https://pmc.ncbi.nlm.nih.gov/articles/PMC10798820/
Duan X, Zhang L, Liao Y, et al. Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet. European Journal of Pharmacology. 2024;969:176440. https://www.sciencedirect.com/science/article/abs/pii/S0014299924001286
Kant R, Chandra L, Verma V, et al. Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus. World Journal of Methodology. 2022;12(4):246–257. https://pmc.ncbi.nlm.nih.gov/articles/PMC9350729/
Tsai CY, Lu HC, Chou YH, et al. Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study. Frontiers in Endocrinology. 2022;12:814770. https://pmc.ncbi.nlm.nih.gov/articles/PMC8793908/
Jordy AB, Albayaty M, Breitschaft A, et al. Effect of oral semaglutide on the pharmacokinetics of levonorgestrel and ethinylestradiol in healthy postmenopausal women and furosemide and rosuvastatin in healthy subjects. Clinical Pharmacokinetics. 2021;60(9):1171–1185. https://pmc.ncbi.nlm.nih.gov/articles/PMC8416862/
Smits MM, Van Raalte DH. Safety of semaglutide. Frontiers in Endocrinology. 2021;12:645563. https://pmc.ncbi.nlm.nih.gov/articles/PMC8294388/
LeValley SL, Tomaro-Duchesneau C, Britton RA. Degradation of the incretin hormone glucagon-like peptide-1 (GLP-1) by Enterococcus faecalis metalloprotease GelE. mSphere. 2020;5(1):e00585-19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7021470/
Kato S, Sato T, Fujita H, Kawatani M, Yamada Y. Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Scientific Reports. 2021;11(1):9167. https://pmc.ncbi.nlm.nih.gov/articles/PMC8080802/
Tonneijck L, Muskiet MHA, Blijdorp CJ, et al. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. American Journal of Physiology-Renal Physiology. 2019;316(2):F231–F240. https://pubmed.ncbi.nlm.nih.gov/30353743/
Xu F, Wang KY, Wang N, Li G, Liu D. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice. PLOS ONE. 2017;12(7):e0181939. https://pmc.ncbi.nlm.nih.gov/articles/PMC5531477/
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Medicine. 2010;27(2):136–142. https://pmc.ncbi.nlm.nih.gov/articles/PMC4232006/
Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes – results of a hyperglycaemic glucose clamp study. Nephrology Dialysis Transplantation. 2006;21(8):2166–2171. https://academic.oup.com/ndt/article/21/8/2166/1820746
US Food and Drug Administration. Ozempic (semaglutide) injection: highlights of prescribing information. Silver Spring (MD): FDA; 2023.